Disease · MONDO_0002026
candidiasis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. candidiasis. Diseases, record MONDO_0002026. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002026
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 20 of its 37 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Drugs37
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MICAFUNGIN | CHEMBL457547 | Small molecule | Approval | EMA Human Drugs and TTD | 8 | 6 | 6 | Drugs and targets |
| CASPOFUNGIN | CHEMBL1630575 | Small molecule | Approval | EMA Human Drugs | 5 | 3 | 3 | Drugs and targets |
| FLUCONAZOLE | CHEMBL106 | Small molecule | Approval | DailyMed | 82 | 2 | 2 | Drugs and targets |
| ANIDULAFUNGIN | CHEMBL264241 | Small molecule | Approval | DailyMed, EMA Human Drugs and TTD | 4 | 1 | 1 | Drugs and targets |
| AMPHOTERICIN B | CHEMBL267345 | Small molecule | Approval | DailyMed | 3 | 1 | 1 | Drugs and targets |
| CASPOFUNGIN ACETATE | CHEMBL5314378 | Small molecule | Approval | DailyMed and PMDA | 3 | 1 | 1 | Drugs and targets |
| VORICONAZOLE | CHEMBL638 | Small molecule | Approval | DailyMed and EMA Human Drugs | 18 | 0 | 0 | Drugs and targets |
| POSACONAZOLE | CHEMBL1397 | Small molecule | Approval | DailyMed and EMA Human Drugs | 4 | 0 | 0 | Drugs and targets |
| GRISEOFULVIN | CHEMBL562 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| CLOTRIMAZOLE | CHEMBL104 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
1 to 10 of 37
See all 37 drugsTargets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MC1R | Melanocyte-stimulating hormone receptor | 1 | Melanocortin receptor 1 agonist | Phase 2 | https://conductscience.org/library/genes/4157 | Drugs and targets |
| MC3R | Melanocortin receptor 3 | 1 | Melanocortin receptor 3 agonist | Phase 2 | https://conductscience.org/library/genes/4159 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
Trials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03363841 | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) | Phase 3 | 30 | 2024-07-03 | Candidiasis, Invasive, Candidemia | IBREXAFUNGERP | Its record names the disease | ClinicalTrials.gov |
| NCT00806351 | An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System | Phase 3 | 21 | 2012-12-20 | Fungemia, Neutropenia, Candidiasis | ANIDULAFUNGIN, CASPOFUNGIN | Its record names the disease | ClinicalTrials.gov |
| NCT01165320 | A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074) | Phase 2 | 20 | 2014-04-23 | Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis | CASPOFUNGIN | Its record names the disease | ClinicalTrials.gov |
| NCT02678598 | A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections | 2,555 | Invasive Fungal Infections | MICAFUNGIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT00889356 | Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis | Phase 3 | 160 | Candidiasis, Bacterial Vaginosis | CLINDAMYCIN, KETOCONAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT01102387 | Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections | Phase 2 | 137 | Candidiasis | OCTENIDINE HYDROCHLORIDE, PREDNICARBATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05434104 | The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study | Not applicable | 114 | Bacterial Vaginosis, Candida Vaginal | FLUCONAZOLE, METRONIDAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT02145832 | Fluconazole Versus Micafungin in Neonates With Candidiasis | Phase 2/3 | 100 | Candidiasis | FLUCONAZOLE, MICAFUNGIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00608335 | Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug | Phase 1 | 84 | Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis | MICAFUNGIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00005920 | Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole | Phase 2 | 70 | Candidiasis, Oral, HIV Infections | CASPOFUNGIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Anidulafungin vs Caspofungin: serious adverse events | 5 of 15 | 4 of 6 | 21 | NCT00806351 | Trial comparisons |
| Participants With Invasive Candidiasis vs Participants With Aspergillosis: serious adverse events | 1 of 12 | 2 of 8 | 20 | NCT01165320 | Trial comparisons |
| Anidulafungin vs Caspofungin: Response Based on Clinical Cure and Microbiological Success at EOIVT | 7 of 8 | 2 of 3 | 11 | NCT00806351 | Trial comparisons |
| Anidulafungin vs Caspofungin: Response Based on Clinical Cure and Microbiological Success at EOT | 6 of 8 | 3 of 3 | 11 | NCT00806351 | Trial comparisons |
| Anidulafungin vs Caspofungin: Response Based on Clinical Cure and Microbiological Success at 2-Week Follow-Up Visit | 4 of 6 | 1 of 1 | 7 | NCT00806351 | Trial comparisons |
| Anidulafungin vs Caspofungin: Response Based on Clinical Cure and Microbiological Success at 6-Week Follow-Up Visit | 6 of 6 | 1 of 1 | 7 | NCT00806351 | Trial comparisons |
Papers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002026
GET https://conductscience.org/api/diseases/v1/MONDO_0002026/drugs?page=2